Across TCGA pan-cancer cohorts, TMEM158 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated TMEM158 data layer compared with 28 for mass-spec protein and 1 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher TMEM158 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM158 expression acts as an unfavorable survival marker.
GBM are the cancer types where TMEM158 mass-spec protein most reproducibly stratifies survival.